Idorsia Wants a Commercial Expert. The Last One Didn't Work Out.

Idorsia is back on the CEO carousel — and this time, the founder is driving.

The Swiss biotech announced March 16 that Dr. Srishti Gupta has stepped down as chief executive, less than a year after taking over the role. Chairman Jean-Paul Clozel, who previously ran Idorsia from its 2017 founding through 2024, will assume day-to-day operations as interim CEO while the board hunts for yet another successor.

The market verdict was swift: Idorsia shares dropped roughly 20% on the news, with an intraday low of CHF 2.84 on March 16 compared to an open of CHF 3.24, according to trading data from the SIX Swiss Exchange.

Gupta tenure was brief and apparently unsatisfying to the board. The press release describes the departure as a mutual agreement, which is the kind of language that usually means one side wanted out more than the other. Clozel thanked her for her commitment on behalf of the board but offered no specifics about what she accomplished or why the relationship did not work out. Gupta, for her part, said she was proud of translating science into meaningful progress for patients.

That language is notable. You do not thank someone for bringing in commercial expertise and then let them go after less than a year unless something went sideways.

The real signal may be in what the board is asking for in a replacement. Clozel said the search will prioritize candidates with extensive pharmaceutical leadership experience and strong commercial expertise. That is a specific ask — and it suggests Idorsia problem is not the science. The company has a solid foundation: it was spun out of Actelion after Johnson & Johnson acquired that company in 2017, and it brought with it a pipeline built on serious pharmacology. Its insomnia drug QUVIVIQ (daridorexant) is a genuine innovation — a dual orexin receptor antagonist that works differently from older sleep aids.

But commercial execution has been elusive. QUVIVIQ launched into a crowded market and has not generated the revenue Idorsia needs to fund its pipeline. The company has been burning cash, and a leadership team that cannot close the gap between scientific promise and commercial reality creates a credibility problem with investors.

This is Idorsia second CEO transition in roughly two years. Clozel ran the company from its 2017 founding until stepping down in 2024, when Gupta took over. That is a company that has not yet found its commercial footing — and the revolving door at the top is a symptom.

The Endpoints headline mentioned a former Jazz executive making a comeback, but that article was behind a paywall and I could not verify who that refers to or whether a formal appointment is imminent. The press release itself only describes an active search, with Clozel as interim.

Clozel returning to the CEO role, even temporarily, is an admission that the board does not trust the handoff to anyone else yet. He is 70 and has been chairman since 2020, stepping down as CEO four years after founding the company. His reinstatement — even as interim — signals instability at the top when what Idorsia needs is a steady hand with commercial instincts.

The board will also propose new independent director candidates at the May 6 AGM, which suggests some governance churn underneath the operational churn.

For now, Idorsia is a biotech with good science, a real product, and a leadership vacuum it has been unable to fill. The next CEO will need to actually sell something.